Phosphodiesterase type 5 (PDE5) inhibitors: looking beyond erectile dysfunction

Br J Cardiol 2003;10(Suppl 4):S1-S8 Leave a comment
Click any image to enlarge
Sponsorship Statement: This is a sponsored supplement to The British Journal of Cardiology. Details of sponsorship can be found by downloading the PDF.

A round-table meeting to discuss the management of erectile dysfunction was held in London in June. Participants heard about the cardiac safety and cardiac potential of PDE5 inhibitors, and agreed a number of points about the clinical benefits and use of these agents. This supplement contains a report of the meeting.

Erectile dysfunction (ED) is common. Though men are reticent about seeking help, some degree of ED is believed to affect up to 52% of men between 40 and 70 years of age. Patients with hypertension, diabetes, a history of smoking and hyperlipidaemia have an increased incidence of ED: about 70% of cases of ED have a vascular origin, and of these roughly half have diabetes. ED may be a marker for other diseases: patients who present with ED should be assessed for previously undiagnosed conditions such as diabetes, ischaemic heart disease, hypertension and benign prostatic hyperplasia. Nonetheless, 80% of patients with ED are at low cardiovascular risk.

Disclaimer: UK prescribing information current at the date of publication of this supplement can be found by downloading the PDF. Medinews Cardiology Limited advises healthcare professionals to consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews Cardiology Limited cannot accept responsibility for any errors in prescribing which may occur.